PENTASA 1 G / 100 ML
MESALAZINE : 1 G / 100 ML · DIN 02153521 · FERRING INC
Health Canada status: MARKETED
What is PENTASA?
PENTASA 1 G / 100 ML contains MESALAZINE : 1 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02153521, held by FERRING INC, supplied as SUSPENSION for RECTAL administration. Health Canada currently lists it as marketed, status dated 09-Nov-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PENTASA used for?
Treatment and maintenance of mild to moderate active ulcerative colitis; management and maintenance of mild to moderate Crohn’s Disease. Suppositories for acute ulcerative proctitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02153521 |
|---|---|
| Brand name | PENTASA |
| Generic / active ingredient | MESALAZINE : 1 G / 100 ML |
| Manufacturer | FERRING INC |
| Strength | 1 G / 100 ML |
| Dosage form | SUSPENSION |
| Route of administration | RECTAL |
| Schedule | Prescription |
| ATC code | A07EC02 MESALAZINE |
| AHFS class | 56:36.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Nov-1999 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Tablets: 2-4 g daily. Enema: 1-4 g daily at bedtime. Suppositories: 1 g daily at bedtime. Tablets must be swallowed whole with meals; do not chew, break, or crush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated). Typical for class is 15-30°C.
How is it supplied?
Tablets: Blister strips of 10. Enemas: 7 per carton with hygienic bags. Suppositories: Blister cards of 5 or 7, cartons of 28 or 30 with finger protectors.
Contraindications
Gastric or duodenal ulcer; urinary tract obstruction, renal parenchymal disease or severe renal impairment; hypersensitivity to salicylates; severe hepatic impairment; infants under 2 years.
Warnings and precautions
Risk of severe cutaneous adverse reactions (SCARs) like SJS/TEN. Acute intolerance syndrome may occur. Potential for nephrotoxicity, hepatotoxicity, and cardiac hypersensitivity.
What can be used instead?
Other Canadian products sharing ATC code A07EC02 MESALAZINE. 18 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEZAVANT | 1.2 G | TABLET (DELAYED AND EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02297558 |
| MEZERA | 1 G | FOAM | AVIR PHARMA INC. | MARKETED | DIN 02474026 |
| MEZERA | 1 G | SUPPOSITORY | AVIR PHARMA INC. | MARKETED | DIN 02474018 |
| MEZERA | 1 G | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02545012 |
| MEZERA | 500 MG | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02524481 |
| OCTASA | 1600 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02529610 |
| OCTASA | 800 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02465752 |
| PENTASA | 1 G | SUPPOSITORY | FERRING INC | MARKETED | DIN 02153564 |
| PENTASA | 1 G | TABLET (EXTENDED-RELEASE) | FERRING INC | MARKETED | DIN 02399466 |
| PENTASA | 4 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | DIN 02153556 |
Who else supplies MESALAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MESALAZINE appears in 884 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.